Pyridine sulfonamides

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• X1 is N or CR3;
• X2 is N or CR4;
• X3 is N or CR5;
• X4 is N or CR6;
• X5 is N or CR7;
• X6 is N or CR8;
• X7 is CR9 or CL1;
• X8 is CR10 or CL1;
• X9 is N or CR11;
• wherein 0, 1, 2, 3, or 4 of X1, X2, X3, X4, X5, X6 and X9 are N;
• R1 is —NH-L2;
• R2 is NH2, NHC1-8alk, NHC1-4haloalk, NH—ORa, NH—ORc, —ORa, or —ORc;
• R3 is H, halo, CN, C1-8alk, or C1-4haloalk;
• R4 is H, halo, CN, C1-8alk, or C1-4haloalk;
• R5 is H, halo, CN, C1-8alk, or C1-4haloalk;
• R6 is H, halo, CN, C1-8alk, or C1-4haloalk;
• R7 is CN, halo, C1-8alk, or C1-8haloalk, —ORa, or —ORc;
• R8 is H, halo, C1-8alk, or C1-8haloalk;
• R9 is H, halo, C1-20alk, or C1-20haloalk;
• R10 is H, halo, C1-8alk, or C1-8haloalk;
• R11 is H, halo, C1-8alk, or C1-8haloalk;
• L1 is C0-6alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 Rd groups selected from F, Cl, Br, C1-6alk —ORa, —ORc, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC1-6alkNRaRa, —OC1-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC1-6alkNRaRa, —NRaC1-6alkORa, and oxo;
• wherein each of said C1-6alk is substituted by 0, 1, 2 or 3 substituents selected from halo, C1-3haloalk, —ORa, —NRaRa, —N(Ra)C(═O)Rb, —OC(═O)Rb, C(═O)NRaRa, or C(═O)ORa
• L2 is C0-6alk-linked saturated, partially-saturated or unsaturated 5- or 6-membered monocyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 Re groups selected from F, Cl, Br, C1-6alk, or C1-4haloalk;
• Ra is independently, at each instance, H or Rb;
• Rb is independently, at each instance, phenyl, benzyl or C1-6alk, wherein the phenyl, benzyl and C1-6alk is substituted by 0, 1, 2 or 3 substituents selected from halo, C1-4alk, C1-3haloalk, —OC1-4alk, —NH2, —NHC1-4alk, and —N(C1-4alk)C1-4alk;
• and
• Rc is a C0-1alk-linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6-, or 7-membered monocyclic or 8-, 9-, 10-, 11-, or 12-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0 or 1 atoms selected from O and S, which is substituted by 0, 1, 2 or 3 R13 groups selected from F, Cl, Br, C1-6alk, C1-4haloalk, —ORa, —OC1-4haloalk, CN, —C(═O)Rb, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —OC(═O)Rb, —OC(═O)NRaRa, —OC2-6alkNRaRa, —OC2-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa, —NRaC2-6alkORa, —C1-6alkNRaRa, —C1-6alkORa, —C1-6alkN(Ra)C(═O)Rb, —C1-6alkOC(═O)Rb, —C1-6alkC(═O)NRaRa, —C1-6alkC(═O)ORa and oxo.